Pulmonary arterial hypertension (PAH) is a rare and progressive condition caused by high blood pressure in the arteries that ...

Using nationwide networks, advanced cytokine profiling, and patient clustering, the team screened over 100 PAH patients to ...

Market opportunities in the Pulmonary Arterial Hypertension (PAH) sector include increased demand for innovative therapies ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the ...

Women who were postpartum with venous thromboembolism (VTE) or abnormal ECGs faced a substantially higher risk for pulmonary ...

Positive topline data from Part B of the TX45 Phase 1b trial demonstrated improvements in both left heart function and pulmonary hemodynamics in ...

Pharmaceuticals’ treatment of pulmonary arterial hypertension was granted FDA orphan designation status, according to a post to ...

Seborrheic dermatitis is linked to other epithelial barrier diseases, supporting the epithelial barrier theory as a shared ...

Sotatercept (Winrevair; Merck) is enhancing treatment for patients with pulmonary arterial hypertension (PAH), explained ...

Following their wedding on October 18, the newlyweds went on their honeymoon to Curaçao, a Dutch Caribbean island and were ...

The link to the live audio webcast of the session is available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be ...